(Q38219491)

31 August 2017

Real-world effectiveness of sitagliptin as add-on therapy in patients with type 2 diabetes mellitus (English)

1 reference

31 August 2017

1 reference

Tse-Ying Chen

1

1 reference

31 August 2017

Ching-Jung Hsieh

series ordinal

2

1 reference

31 August 2017

language of work or name

English

0 references

publication date

1 May 2014

1 reference

31 August 2017

Postgraduate Medicine

1 reference

31 August 2017

126

1 reference

31 August 2017

3

1 reference

31 August 2017

205-215

1 reference

Epidemic obesity and type 2 diabetes in Asia

31 August 2017

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2768

Cardiovascular outcomes in trials of oral diabetes medications: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2768

Standards of medical care in diabetes--2013

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2768

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2768

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2768

Oral antihyperglycemic therapy for type 2 diabetes: scientific review

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2768

Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2768

Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2768

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2768

The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2768

Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2768

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2768

Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2768

Sitagliptin: Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2768

Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2768

Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2768

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2768

Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2768

Use of silkworms for identification of drug candidates having appropriate pharmacokinetics from plant sources

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2768

Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2768

Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2768

Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2768

Clinical characteristics of the responders to dipeptidyl peptidase-4 inhibitors in Korean subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2768

The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2768

Incretin therapies: effects beyond glycemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2768

Neuroprotective properties of GLP-1: theoretical and practical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2768

Effect of initial combination therapy with sitagliptin and metformin on β-cell function in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2768

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.05.2768

21 January 2018

Identifiers

DOI

10.3810/PGM.2014.05.2768

1 reference

release_rfqbcg5hknejzd6oplcbny5tdy

31 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/rfqbcg5hknejzd6oplcbny5tdy

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference